B. Coudert

J. Pignon, B. Chetaille, J. Solassol, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase II study of XR5000 (DACA) administered as a 120-h infusion in patients with recurrent glioblastoma multiforme.

M. J. van den Bent, D. Lacombe, M. Campone, 2002, Annals of Oncology.

Ixabepilone alone or with cetuximab as first-line treatment for advanced/metastatic triple-negative breast cancer.

R. Vyzula, M. Campone, J. Jassem, 2015, Clinical breast cancer.

Multicentre phase II study of imatinib mesylate in patients with recurrent glioblastoma: An EORTC: NDDG/BTG Intergroup Study.

M. J. van den Bent, D. Lacombe, E. Raymond, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

IFCT-1502 CLINIVO: real-world evidence of long-term survival with nivolumab in a nationwide cohort of patients with advanced non-small-cell lung cancer

J. Mazières, W. Hilgers, F. Barlesi, 2021, ESMO open.

Multicentre phase II study of imatinib mesylate in patients with recurrent anaplastic oligodendroglioma (AOD)/mixed oligoastrocytoma (MOA) and anaplastic astrocytoma (AA)/low grade astrocytoma (LGA): An EORTC New Drug Development Group (NDDG) and Brain Tumor Group (BTG) study

R. Stupp, A. Brandes, D. Lacombe, 2005 .

Personalized Reimbursement Model (PRM) program: A real-world data platform of cancer drugs use to improve and personalize drug pricing and reimbursement in France

D. Pérol, B. Coudert, Camille Bachot, 2022, PloS one.

Iniparib administered weekly or twice-weekly in combination with gemcitabine/carboplatin in patients with metastatic triple-negative breast cancer: a phase II randomized open-label study with pharmacokinetics

R. Paridaens, A. Jager, J. Verweij, 2019, Breast Cancer Research and Treatment.

Pathologic Complete Response to Neoadjuvant Chemotherapy of Breast Carcinoma Is Associated with the Disappearance of Tumor-Infiltrating Foxp3+ Regulatory T Cells

B. Chauffert, P. Fumoleau, F. Ghiringhelli, 2008, Clinical Cancer Research.

Sex moderates circadian chemotherapy effects on survival of patients with metastatic colorectal cancer: a meta-analysis.

S. Iacobelli, F. Lévi, S. Giacchetti, 2012 .

Feasibility of using intraperitoneal epinephrine and cisplatin in patients with advanced peritoneal carcinomatosis

B. Chauffert, P. Fumoleau, P. Fargeot, 2006, Anti-cancer drugs.

Diastolic or systolic left and right ventricular impairment at moderate doses of anthracycline?

Y. Cottin, C. Touzery, P. Louis, 1996, European Journal of Nuclear Medicine.

Comparison of epirubicin and doxorubicin cardiotoxicity induced by low doses: Evolution of the diastolic and systolic parameters studied by radionucide angiography

Y. Cottin, C. Touzery, P. Louis, 1998, Clinical cardiology.

Impairment of diastolic function during short-term anthracycline chemotherapy.

Y. Cottin, C. Touzery, P. Louis, 1995, British heart journal.

Changes in 18 F-FDG tumor metabolism after a ﬁ rst course of neoadjuvant chemotherapy in breast cancer: in ﬂ uence of tumor subtypes

P. Fumoleau, L. Arnould, A. Cochet, 2012 .

Treatment patterns, clinical outcomes and health care costs associated with her2-positive breast cancer with central nervous system metastases: a French multicentre observational study

I. Durand-zaleski, P. Cottu, M. Gutiérrez, 2013, BMC Health Services Research.

Prognostic role of pregnancy occurring before or after treatment of early breast cancer patients aged <35 years

M. Namer, B. Asselain, M. Spielmann, 2009, Cancer.

Visceral osteopathic manipulative treatment reduces patient reported digestive toxicities induced by adjuvant chemotherapy in breast cancer: A randomized controlled clinical study.

A. Bertaut, I. Desmoulins, B. Coudert, 2019, European journal of obstetrics, gynecology, and reproductive biology.

Amiodarone pneumonitis. Bronchoalveolar lavage findings in 15 patients and review of the literature.

F. Bailly, P. Camus, B. Coudert, 1992, Chest.

Spontaneous pyopneumothorax in patients treated with mTOR inhibitors for subpleural pulmonary metastases

F. Ghiringhelli, S. Ladoire, B. Coudert, 2010, Medical oncology.

Phase III trial of chemotherapy using 5-fluorouracil and streptozotocin compared with interferon alpha for advanced carcinoid tumors: FNCLCC-FFCD 9710.

P. Rougier, J. Raoul, J. Seitz, 2009, Endocrine-related cancer.

Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE).

M. Lux, R. Greil, A. Schneeweiss, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

An open-label randomized, multicenter, phase II study on neoadjuvant treatment with trastuzumab plus docetaxel versus trastuzumab plus docetaxel plus bevacizumab according to positron emission tomography (PET) value modification in patients with early stage HER2-positive breast cancer (AVATAXHER): D

J. Darcourt, T. Petit, J. Pierga, 2012 .

Phase II study of bevacizumab with liposomal doxorubicin for patients with platinum- and taxane-resistant ovarian cancer

S. Iacobelli, F. Lévi, S. Giacchetti, 2012 .

A Randomized Multicenter Study of Optimal Circadian Time of Vinorelbine Combined with Chronomodulated 5‐Fluorouracil in Pretreated Metastatic Breast Cancer Patients: EORTC Trial 05971

T. Gorlia, F. Lévi, S. Giacchetti, 2008, Chronobiology international.

Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: the European Organisation for Research and Treatment of Cancer Chronotherapy Group.

Stefano Iacobelli, Francis Lévi, Antoine Adenis, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[Pneumopathy caused by methotrexate].

F. Massin, P. Foucher, P. Camus, 1990, Revue des maladies respiratoires.

Novel tubulin-targeting agents: anticancer activity and pharmacologic profile of epothilones and related analogues.

P. Fumoleau, N. Isambert, E. Ferrant, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

Is immunohistochemistry less sensitive than quantitative reverse transcriptase polymerase chain reaction for hormone receptor status determination in breast cancer?

P. Fumoleau, L. Arnould, B. Coudert, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

MDR1 and thymidylate synthase (TS) gene expressions in advanced breast cancer: relationships to drug exposure, p53 mutations, and clinical outcome of the patients.

S. Lizard-Nacol, P. Fargeot, P. Genne, 1999, Anticancer research.

Diagnostic and predictive value of skin testing in platinum salt hypersensitivity.

Pierre Vabres, S. Dalac, V. Leguy-Seguin, 2007, The Journal of allergy and clinical immunology.

Long-term outcomes in patients with PET-predicted poor-responsive HER2-positive breast cancer treated with neoadjuvant bevacizumab added to trastuzumab and docetaxel: 5-year follow-up of the randomised Avataxher study

T. Petit, J. Prevost, J. Pierga, 2020, EClinicalMedicine.

Lipid A OM-174 increases the natural killer activity of peripheral blood cells from breast cancer patients

L. Arnould, M. Maynadié, C. Bélichard, 1999 .

Bronchoalveolar Lavage Findings in 15 Patients and Review of the Literature

P. Camus, B. Coudert, F. André, 2017 .

Marimastat may not improve survival over placebo following induction therapy for small-cell lung cancer.

B. Coudert, 2003, Cancer treatment reviews.

Phase II study of XR 5000 ( DACA ) administered as a 120-h infusion in patients with recurrent glioblastoma multiforme

D. Lacombe, M. Bent, M. Campone, 2002 .

Benefit of the Sequential Administration of Docetaxel after Standard FEC Regimen for Node-Positive Breast Cancer: Long-Term Follow-Up Results of the FNCLCC-PACS 01 Trial.

T. Delozier, M. Campone, T. Petit, 2009 .

Primary Resistance to Afatinib in a Patient with Lung Adenocarcinoma Harboring Uncommon EGFR Mutations: S768I and V769L.

R. Boidot, Julie Niogret, B. Coudert, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Evolution in the real-world therapeutic strategies in more than 20,000 women with breast cancer having received human epidermal growth factor receptor 2-targeted treatments: Results from the french personalized reimbursement model database (2011-2018).

X. Pivot, P. Cottu, N. Chalabi, 2020, European journal of cancer.

Impact of age at diagnosis of metastatic breast cancer on overall survival in the real-life ESME metastatic breast cancer cohort

M. Campone, T. Petit, M. Mouret-Reynier, 2020, Breast.

Results of a phase I trial of intravenous vinorelbine plus oral capecitabine as first-line chemotherapy of metastatic breast cancer.

B. Chauffert, P. Fumoleau, N. Isambert, 2008, Breast.

Seroprevalence of SARS-CoV-2 among the staff and patients of a French cancer centre after first lockdown: The canSEROcov study

C. Coutant, A. Bertaut, Jean-David Fumet, 2021, European Journal of Cancer.

Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases

S. Gettinger, E. Felip, L. Crinò, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Types of interaction of amphiphilic drugs with phospholipid vesicles.

T M Dwyer, T. Dwyer, H. Mehendale, 1988, The Journal of pharmacology and experimental therapeutics.

Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer

S. Gettinger, E. Felip, L. Crinò, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Predictive Factors of Response in HER2-Positive Breast Cancer Treated by Neoadjuvant Therapy

S. Guiu, B. Coudert, M. M. Reynier, 2013, Journal of oncology.

Monitoring HSP70 exosomes in cancer patients’ follow up: a clinical prospective pilot study

P. Pagès, C. Coutant, C. Garrido, 2020, Journal of extracellular vesicles.

Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?

F. Penault-Llorca, F. Bonnetain, L. Arnould, 2006, British Journal of Cancer.

Exome Analysis Reveals Genomic Markers Associated with Better Efficacy of Nivolumab in Lung Cancer Patients

R. Boidot, Jean-David Fumet, F. Ghiringhelli, 2018, Clinical Cancer Research.

Response to first line chemotherapy regimen is associated with efficacy of nivolumab in non-small-cell lung cancer

R. Boidot, P. Saintigny, Jean-David Fumet, 2017, Oncoimmunology.

Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study.

Denis Lacombe, Johan M Kros, R. Stupp, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Next-generation sequencing analysis of lung and colon carcinomas reveals a variety of genetic alterations.

R. Boidot, P. Fumoleau, F. Ghiringhelli, 2014, International journal of oncology.

Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study--trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01).

P. Petrow, S. Culine, X. Pivot, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Use of dedicated gene panel sequencing using next generation sequencing to improve the personalized care of lung cancer

Laurent Arnould, R. Boidot, F. Ghiringhelli, 2016, Oncotarget.

BioCAST/IFCT-1002: epidemiological and molecular features of lung cancer in never-smokers

H. Blanché, J. Trédaniel, G. Zalcman, 2015, European Respiratory Journal.

Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy?

S. Culine, X. Pivot, J. Douillard, 2007, British Journal of Cancer.

Tim-3/galectin-9 pathway and mMDSC control primary and secondary resistances to PD-1 blockade in lung cancer patients

Jean-David Fumet, F. Ghiringhelli, C. Richard, 2019, Oncoimmunology.

Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer.

F. Lévi, S. Giacchetti, C. Focan, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy.

G. Giaccone, T. Ciuleanu, W. Brugger, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node-positive breast cancer: the 8-year follow-up results of the UNICANCER-PACS01 trial.

J. Machiels, F. Penault-Llorca, B. Asselain, 2012, The oncologist.

Sequential two-line strategy for stage IV non-small-cell lung cancer: docetaxel-cisplatin versus vinorelbine-cisplatin followed by cross-over to single-agent docetaxel or vinorelbine at progression: final results of a randomised phase II study.

D. Caillaud, D. Spaeth, A. Monnier, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

HER2-positive breast cancer: 18F-FDG PET for early prediction of response to trastuzumab plus taxane-based neoadjuvant chemotherapy

C. Coutant, P. Fumoleau, F. Brunotte, 2014, European Journal of Nuclear Medicine and Molecular Imaging.

Pathological response and survival after neoadjuvant therapy for breast cancer: a 30-year study.

C. Coutant, P. Fumoleau, F. Bonnetain, 2013, Breast.

Changes in 18F-FDG tumor metabolism after a first course of neoadjuvant chemotherapy in breast cancer: influence of tumor subtypes.

P. Fumoleau, F. Brunotte, L. Arnould, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Evaluation of Breast Tumor Blood Flow with Dynamic First-Pass 18F-FDG PET/CT: Comparison with Angiogenesis Markers and Prognostic Factors

Alexandre Cochet, Olivier Humbert, François Brunotte, 2012, The Journal of Nuclear Medicine.

[18F]FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy

P. Fumoleau, C. Touzery, F. Brunotte, 2007, European Journal of Nuclear Medicine and Molecular Imaging.

Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3

J. Pignon, C. Chouaid, E. Quoix, 2011, European Respiratory Journal.

Comparative cost-effectiveness of three strategies for guiding second-line erlotinib initiation in non small-cell lung cancer: a French prospective multicenter study (ERMETIC Project Part 3) Short title: Erlotinib cost-effectiveness analysis in second-line lung cancer therapy

Isabelle, C. Chouaid, É. Dansin, 2011 .

Does large NGS panel analysed using exome tumour sequencing improve the management of advanced non-small-cell lung cancers?

R. Boidot, F. Ghiringhelli, L. Arnould, 2021, Lung cancer.

Phase I II M ulticenter R andomized T rial o f O xaliplatin Added t o C hronomodulated F luorouracil-Leu covorin a s First-Line T reatment o f M etastatic C olorectal C ancer

S. Giacchetti, C. Focan, P. Chollet, 2000 .

T-bet expression in intratumoral lymphoid structures after neoadjuvant trastuzumab plus docetaxel for HER2-overexpressing breast carcinoma predicts survival

P. Fumoleau, S. Ladoire, L. Arnould, 2011, British Journal of Cancer.

Parallel evolution and differences in seroprevalence of SARS-CoV-2 antibody between patients with cancer and health care workers in a tertiary cancer centre during the first and second wave of COVID-19 pandemic: canSEROcov-II cross-sectional study

C. Coutant, A. Bertaut, Jean-David Fumet, 2022, European Journal of Cancer.

Prognostic and predictive role of CD8 and PD-L1 determination in lung tumor tissue of patients under anti-PD-1 therapy

R. Boidot, P. Saintigny, Jean-David Fumet, 2018, British Journal of Cancer.

Presence of Foxp 3 expression in tumor cells predicts better survival in HER 2-overexpressing breast cancer patients treated with neoadjuvant chemotherapy

B. Chauffert, P. Fumoleau, J. Vincent, 2010 .

Presence of Foxp3 expression in tumor cells predicts better survival in HER2-overexpressing breast cancer patients treated with neoadjuvant chemotherapy

B. Chauffert, P. Fumoleau, J. Vincent, 2010, Breast Cancer Research and Treatment.

Pathologic Complete Response to Trastuzumab-Based Neoadjuvant Therapy Is Related to the Level of HER-2 Amplification

F. Penault-Llorca, P. Arveux, P. Fumoleau, 2007, Clinical Cancer Research.

Pathological complete response and survival according to the level of HER-2 amplification after trastuzumab-based neoadjuvant therapy for breast cancer

F. Penault-Llorca, P. Fumoleau, S. Ladoire, 2010, British Journal of Cancer.

Variations in Gene Expression and Response to Neoadjuvant Chemotherapy in Breast Carcinoma

F. Végran, R. Boidot, P. Fumoleau, 2009, Cancer investigation.

Long-term recurrence of secretory breast carcinoma with metastatic sentinel lymph nodes

L. Arnould, S. Guiu, C. Loustalot, 2011, Archives of Gynecology and Obstetrics.

Randomized multicenter phase II study comparing a combination of fluorouracil and folinic acid and alternating irinotecan and oxaliplatin with oxaliplatin and irinotecan in fluorouracil-pretreated metastatic colorectal cancer patients.

J. Pierga, Y. Bécouarn, J. Raoul, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial.

J. Machiels, T. Delozier, F. Penault-Llorca, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival

C. Coutant, P. Fumoleau, F. Ghiringhelli, 2011, The Journal of pathology.

[The anti-tumor immune response in breast cancer: Update and therapeutic perspectives].

P. Fumoleau, F. Ghiringhelli, S. Ladoire, 2017, Annales de pathologie.

Circadian rhythm in rest and activity: a biological correlate of quality of life and a predictor of survival in patients with metastatic colorectal cancer.

S. Iacobelli, T. Gorlia, F. Lévi, 2009, Cancer research.

Five-year outcomes from the randomized, phase 3 trials CheckMate 017/057: nivolumab vs docetaxel in previously treated NSCLC

S. Gettinger, L. Crinò, E. Vokes, 2020 .

Hepatic arterial infusion of cisplatin diluted in hypotonic 25 g/l glucose solution administered in balloon-occluded hepatic artery: experimental rationale and clinical pilot study.

B. Chauffert, P. Fargeot, N. Isambert, 2001, Journal of experimental & clinical cancer research : CR.

Phase II study of XR 5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with non-small cell lung cancer.

D. Lacombe, M. Salzberg, X. Paoletti, 2003, European journal of cancer.

Multicenter phase II trial of neoadjuvant therapy with trastuzumab, docetaxel, and carboplatin for human epidermal growth factor receptor-2-overexpressing stage II or III breast cancer: results of the GETN(A)-1 trial.

B. Weber, M. Namer, M. Campone, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Nilutamide pneumonitis: a report on eight patients.

P. Pfitzenmeyer, P. Foucher, P. Camus, 1992, Thorax.

Baseline diastolic dysfunction as a predictive factor of trastuzumab-mediated cardiotoxicity after adjuvant anthracycline therapy in breast cancer

P. Fumoleau, Y. Cottin, C. Touzery, 2011, Breast Cancer Research and Treatment.

Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials.

P. Couzigou, M. Ducreux, C. Borel, 2018, European journal of cancer.

Circadian concepts in normal and neoplastic breast

B. Coudert, 2002, Chronobiology international.

Role of positron emission tomography for the monitoring of response to therapy in breast cancer.

P. Fumoleau, F. Brunotte, A. Cochet, 2015, The oncologist.

Impact of neoadjuvant chemotherapy on survival in breast cancer patients in daily practice: a population-based study.

P. Maingon, P. Arveux, P. Fumoleau, 2013, European journal of cancer care.

[Clinical value of the estimation of growth kinetics of primary ovarian cancer recurrences by CA125 doubling time].

I. Barillot, P. Fargeot, J. Riedinger, 1997, Bulletin du cancer.

[Erratum to: "Breast cancer screening: On our way to the future" [Bull. Cancer 103 (2016) 753-763]].

M. Espié, D. Cox, R. Rouzier, 2016, Bulletin du cancer.

Prediction of overall survival through circadian rest‐activity monitoring during chemotherapy for metastatic colorectal cancer

S. Iacobelli, X. Durando, S. Giacchetti, 2012, International journal of cancer.

A multicenter phase II study with triptorelin (sustained-release LHRH agonist) in advanced or recurrent endometrial carcinoma: a French anticancer federation study.

É. Luporsi, T. Lesimple, C. Lhommé, 1999, Gynecologic oncology.

Roleof Positron Emission Tomography for theMonitoring of Response to Therapy in Breast Cancer

P. Fumoleau, F. Brunotte, A. Cochet, 2015 .

A decrease in brown adipose tissue activity is associated with weight gain during chemotherapy in early breast cancer patients

A. Ginzac, É. Gadéa, X. Durando, 2020, BMC Cancer.

Use of [(18)F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [(18)F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial.

Thomas Bachelot, Thierry Petit, Pierre Kerbrat, 2014, The Lancet. Oncology.

Lack of everolimus diffusion in pleural fluid during pleural progression of breast cancer: A case report

Antonin Schmitt, B. Coudert, F. Goirand, 2020, Journal of Oncology Pharmacy Practice.

Metastatic inflammatory breast cancer: survival outcomes and prognostic factors in the national, multicentric, and real-life French cohort (ESME)

F. Bertucci, M. Campone, T. Petit, 2021, ESMO open.

Sequential addition of an anthracycline-based regimen to docetaxel as neoadjuvant chemotherapy in patients with operable breast cancer.

F. Penault-Llorca, M. Mouret-Reynier, P. Chollet, 2006, Clinical breast cancer.

Pre-operative systemic (neo-adjuvant) therapy with trastuzumab and docetaxel for HER2-overexpressing stage II or III breast cancer: results of a multicenter phase II trial.

B. Weber, P. Fumoleau, L. Vanlemmens, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Long-term follow-up of HER2-overexpressing stage II or III breast cancer treated by anthracycline-free neoadjuvant chemotherapy.

B. Weber, M. Campone, I. van Praagh, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial

C. Tournigand, M. Espié, B. Weber, 2019, The Lancet.

Abstract 1296: MEK inhibition overcomes chemoimmunotherapy resistance by inducing CXCL10 in cancer cells

Jean-David Fumet, F. Ghiringhelli, S. Ladoire, 2022, Cancer Research.

Pharmacokinetics and metabolism of nilutamide in the isolated rat lung.

P. Foucher, P. Camus, P. D'athis, 1991, The Journal of pharmacology and experimental therapeutics.

p53 gene alterations are associated with a decreased responsiveness to neoadjuvant chemotherapy in human breast cancer.

P. Fargeot, J. Riedinger, B. Coudert, 1997, International Journal of Oncology.

Role of positron emission tomography for the monitoring of response to therapy in breast cancer.

Alexandre Cochet, Olivier Humbert, Salim Kanoun, 2015, The Oncologist.

Phase II trial with ISIS 5132 in patients with small-cell (SCLC) and non-small cell (NSCLC) lung cancer. A European Organization for Research and Treatment of Cancer (EORTC) Early Clinical Studies Group report.

M. Borner, J. Smyth, P. Fumoleau, 2001, European journal of cancer.

Tumor clock protein PER2 as a determinant of survival in patients (pts) receiving oxaliplatin-5-FU-leucovorin as first-line chemotherapy for metastatic colorectal cancer (MCC)

S. Iacobelli, F. Lévi, S. Giacchetti, 2008 .

Transcriptional expression of 8 genes predicts pathological response to first-line docetaxel + trastuzumab-based neoadjuvant chemotherapy

F. Végran, R. Boidot, P. Fumoleau, 2015, BMC Cancer.

Age and prognosis of non-small cell lung cancer. Usefulness of a relative survival model.

J. Faivre, P. Arveux, A. Bernard, 1993, European journal of cancer.

Antibiotic Use Does Not Appear to Influence Response to Nivolumab.

R. Boidot, Jean-David Fumet, F. Ghiringhelli, 2017, Anticancer research.

Management and outcome of male metastatic breast cancer in the national multicenter observational research program Epidemiological Strategy and Medical Economics (ESME)

S. Mathoulin-Pélissier, T. Petit, O. Trédan, 2020, Therapeutic advances in medical oncology.

Predictive factors of pathologic complete response of HER2-positive breast cancer after preoperative chemotherapy with trastuzumab: development of a specific predictor and study of its utilities using decision curve analysis

R. Rouzier, F. Reyal, C. Coutant, 2016, Breast Cancer Research and Treatment.

18F-FDG PET/CT provides powerful prognostic stratification in the primary staging of large breast cancer when compared with conventional explorations

C. Coutant, P. Fumoleau, F. Brunotte, 2014, European Journal of Nuclear Medicine and Molecular Imaging.

Feasibility and safety of weekly sequential epirubicin-paclitaxel as adjuvant treatment for operable breast cancer patients older than 70 years.

V. Quipourt, P. Fumoleau, F. Ghiringhelli, 2011, Clinical breast cancer.

Effect of pregnancy, in the year prior and after treatment for breast carcinoma, on survival and recurrence in women with breast cancer younger than 35 years. GETNA GROUP.

M. Namer, B. Asselain, M. Spielmann, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

1301PDThree-year follow-up from CheckMate 017/057: Nivolumab versus docetaxel in patients with previously treated advanced non-small cell lung cancer (NSCLC)

Burgio, S. Gettinger, L. Crinò, 2017 .

[Diagnostic value of broncho-alveolar lavage in lung diseases caused by amiodarone].

E. Solary, P. Foucher, P. Camus, 1989, Presse medicale.

[Nitrosourea-induced lung diseases].

F. Massin, P. Foucher, P. Camus, 1992, Revue des maladies respiratoires.

Gene expression profile and response to trastuzumab–docetaxel-based treatment in breast carcinoma

D. Dembélé, F. Végran, R. Boidot, 2009, British Journal of Cancer.

Population pharmacokinetics and exposure–response relationship of trastuzumab and bevacizumab in early-stage breast cancer

I. Navarro-Teulon, G. Paintaud, D. Ternant, 2021, European Journal of Clinical Pharmacology.

Taxane rechallenge during metastatic disease in HER-2 negative breast cancer patients: Clinical activity, tolerance and survival results

A. Bertaut, S. Ladoire, C. Kaderbhai, 2023, Breast.

Subcutaneous interleukin‐2 and interferon α in the treatment of patients with metastatic renal cell carcinoma—Less efficacy compared with intravenous interleukin‐2 and interferon α

A. Ravaud, J. Douillard, C. Chevreau, 2002 .

Somatic profile in lung cancers is associated to reproductive factors in never-smokers women: Results from the IFCT-1002 BioCAST study.

J. Mazières, C. Dubos-Arvis, É. Dansin, 2020, Respiratory medicine and research.

[Tricuspid endocarditis with right-left auricular shunt through a patent foramen ovale].

P. Louis, J. Eicher, H. Diebold, 1987, Annales de cardiologie et d'angeiologie.

Multifocal malignant fibrous histiocytoma of the spine.

L. Arnould, J. Maillefert, C. Piroth, 1997, Revue du rhumatisme.

OA14.04 Five-Year Outcomes From the Randomized, Phase 3 Trials CheckMate 017/057: Nivolumab vs Docetaxel in Previously Treated NSCLC

S. Gettinger, L. Crinò, E. Vokes, 2019, Journal of Thoracic Oncology.

Durable response of lung carcinoma patients to EGFR tyrosine kinase inhibitors is determined by germline polymorphisms in some immune-related genes

R. Boidot, Stefano Kim, L. Arnould, 2023, Molecular Cancer.

Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial

R. Greil, O. Popovych, C. Gridelli, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Randomized phase II study of gemcitabine-oxaliplatin or gemcitabine-cisplatin in chemonaive patients with advanced non-small cell lung cancer (NSCLC)-CLEO 05.

J. Pujol, T. le Chevalier, X. Sun, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Neoadjuvant therapy for breast cancer has no benefits on overall survival or on the mastectomy rate in routine clinical practice. A population-based study with a median follow-up of 11 years using propensity score matching.

P. Maingon, P. Arveux, P. Fumoleau, 2012, European journal of cancer.

Benefit of neoadjuvant capecitabine + epirubicin + cyclophosphamide (CEX) versus 5-FU + epirubicin + cyclophosphamide (FEC) for operable breast cancer (BC) followed by adjuvant docetaxel (T)

F. Penault-Llorca, G. Milano, P. Fumoleau, 2008 .

Correction: Prognostic and predictive role of CD8 and PD-L1 determination in lung tumor tissue of patients under anti-PD-1 therapy

R. Boidot, P. Saintigny, Jean-David Fumet, 2019, British Journal of Cancer.

Circadian rhythm in rest and activity: a biological correlate of quality of life and a predictor of survival in patients with metastatic colorectal cancer.

S. Iacobelli, T. Gorlia, F. Lévi, 2009, Cancer research.

[Poor prognostic value of weight change during chemotherapy in non-metastatic breast cancer patients: causes, mechanisms involved and preventive strategies].

Y. Bignon, B. Morio, X. Durando, 2013, Bulletin du cancer.

S. Iacobelli, T. Gorlia, F. Lévi, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

CPT-11 and L-OHP combination versus alternated combination of LV5FU2 + CPT-11/LV5FU2 + L-OHP in 5-FU resistant advanced colorectal cancer (CRC): Preliminary results

Y. Bécouarn, E. Gamelin, M. Mousseau, 1999 .

9158 A phase III study of erlotinib as maintenance therapy in NSCLC to delay progression following first-line chemotherapy (SATURN)

G. Giaccone, F. Cappuzzo, Keunchil Park, 2009 .